Skip to content
SPC Logo

Buprenorphine 8.0mg Sublingual Tablets

Last Updated on eMC 03-Mar-2016 View document  | Thornton & Ross Ltd Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 03-Mar-2016 and displayed until Current

Reasons for adding or updating:

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Date of revision of text on the SPC: 25-Feb-2016

Legal Category:POM

Black Triangle (CHM): NO

Free-text change information supplied by the pharmaceutical company:

´╗┐Sections 4.2, 4.4, 4.5, 4.6 and 4.8 updated in line with company core data sheet

Updated on 27-Mar-2015 and displayed until 03-Mar-2016

Reasons for adding or updating:

  • New SPC for new product

Legal Category:POM

Black Triangle (CHM): NO

Company contact details

Thornton & Ross Ltd

Company image
Address

Linthwaite, Huddersfield, West Yorks, HD7 5QH

Medical Information e-mail
Medical Information Direct Line

+44 (0) 1484 848164

Customer Care direct line

+44(0)1484 848200

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

buprenorphine hydrochloride

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue